Answers are grounded in this paper and cite their sources.
Lactate is now recognized as an active immunometabolic regulator in the tumor microenvironment (TME), not simply as a glycolytic byproduct. Its immunological effects arise through several related but distinct routes. Extracellular acidosis, glucose competition, and impaired monocarboxylate transporter‐dependent flux can impair CD8 + T cells, natural killer cells, and dendritic cells. Lactate‐ and proton‐sensing receptors can also favor suppressive myeloid and regulatory‐cell programs. Histone and non‐histone lactylation add another layer by linking lactate availability to chromatin regulation and protein function. During sustained or repeated metabolic stress, these processes may support regulatory T‐cell fitness, suppressive programs in tumor‐associated macrophages and myeloid‐derived suppressor cells, checkpoint expression, and resistance to immunotherapy. Lactylation is a plausible mediator through which sustained metabolic stress may be converted into persistent immune reprogramming; however, post‐withdrawal persistence and cellular memory remain to be demonstrated in cancer. We distinguish lactate‐dependent regulation from acidosis and evaluate the links to immune dysfunction and treatment resistance by their temporal, causal, and clinical support. This framework defines tests of post‐exposure persistence and connects mechanistic evidence and pharmacological specificity to biomarker development and mechanism‐matched trial design.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: